Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals announced it will release its financial results for the first half of 2025 on August 21, 2025, followed by an investor webcast and conference call. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market position and investor confidence.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, the company operates internationally in the United States, Brazil, Canada, Europe, and Japan, focusing on addressing unmet medical needs in oncology and rare diseases.
Average Trading Volume: 1,425,477
Technical Sentiment Signal: Buy
Current Market Cap: A$7.14B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.